Jakob Michaelis, Ruth Himmelsbach, Patrick Metzger, Silke Lassmann, Melanie Börries, Martin Werner, Cornelius Miething, Rouven Höfflin, Anna L Illert, Justus Duyster, Heiko Becker, August Sigle, Christian Gratzke, Markus Grabbert
PURPOSE: Personalized medicine poses great opportunities and challenges. While therapeutic landscape markedly expands, descriptions about status, clinical implementation and real-world benefits of precision oncology and molecular tumor boards (MTB) remain sparse, particularly in the field of genitourinary (GU) cancer. Hence, this study characterized urological MTB cases to better understand the potential role of MTB in uro-oncology. METHODS: We analyzed patients with complete data sets being reviewed at an MTB from January 2019 to October 2022, focusing on results of molecular analysis and treatment recommendations...
April 16, 2024: Urologia Internationalis